专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US07713702B2 Biomarkers for diagnosing schizophrenia and bipolar disorder 失效
标题翻译：用于诊断精神分裂症和双相情感障碍的生物标志物
公开(公告)号：US07713702B2
公开(公告)日：2010-05-11
申请号：US12287629
申请日：2008-10-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。

22. 发明申请

US20130165336A1 Biomarkers for Diagnosing Schizophrenia and Bipolar Disorder 审中-公开
标题翻译：用于诊断精神分裂症和双相障碍的生物标志物
公开(公告)号：US20130165336A1
公开(公告)日：2013-06-27
申请号：US13603094
申请日：2012-09-04
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： G01N21/64
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。

23. 发明申请

US20100099086A1 Method and apparatus for determining a probability of colorectal cancer in a subject 有权
标题翻译：用于确定受试者中结肠直肠癌概率的方法和装置
公开(公告)号：US20100099086A1
公开(公告)日：2010-04-22
申请号：US12384914
申请日：2009-04-10
申请人： Choong-Chin Liew , Samuel Chao
发明人： Choong-Chin Liew , Samuel Chao
IPC分类号： C12Q1/68 , C12N9/10 , C07H21/00 , C07H21/02 , C07H21/04 , G06F17/10
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , C12Q2600/166 , G01N33/57419 , G01N2800/50 , G01N2800/56 , G06F19/12 , G06F19/20 , G06F19/24
摘要： A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer.
摘要翻译：公开了一种确定人类受试者具有结肠直肠癌而不是不具有结肠直肠癌的可能性的方法。对于选自ANXA3，CLEC4D，IL2RB，LMNB1，PRRG4，TNFAIP6和VNN1的一组或多种基因的每个基因，该方法包括：测定受试对象的血液中基因编码的RNA水平从而生成测试数据; 提供表示具有结肠直肠癌的人类对照受试者的血液中基因编码的RNA水平的阳性对照数据，并提供表示不具有结肠直肠癌的人类对照受试者的血液中由该基因编码的RNA水平的阴性对照数据; 并且确定测试数据对应于阳性对照数据而不是阴性对照数据的概率，其中测试数据对应于阳性对照数据而不是阴性对照数据的概率表示测试对象具有结肠直肠癌相对于没有结肠直肠癌。

24. 发明授权

US08921074B2 Method and apparatus for determining a probability of colorectal cancer in a subject 有权
标题翻译：用于确定受试者中结肠直肠癌概率的方法和装置
公开(公告)号：US08921074B2
公开(公告)日：2014-12-30
申请号：US12384914
申请日：2009-04-10
申请人： Choong-Chin Liew , Samuel Chao
发明人： Choong-Chin Liew , Samuel Chao
IPC分类号： C12P19/34 , G01N33/574 , C12Q1/68 , G06F19/24 , G06F19/20
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , C12Q2600/166 , G01N33/57419 , G01N2800/50 , G01N2800/56 , G06F19/12 , G06F19/20 , G06F19/24
摘要： A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer.
摘要翻译：公开了一种确定人类受试者具有结肠直肠癌而不是不具有结肠直肠癌的可能性的方法。对于选自ANXA3，CLEC4D，IL2RB，LMNB1，PRRG4，TNFAIP6和VNN1的一组或多种基因的每个基因，该方法包括：测定受试对象的血液中基因编码的RNA水平从而生成测试数据; 提供表示具有结肠直肠癌的人类对照受试者的血液中基因编码的RNA水平的阳性对照数据，并提供表示不具有结肠直肠癌的人类对照受试者的血液中由该基因编码的RNA水平的阴性对照数据; 并且确定测试数据对应于阳性对照数据而不是阴性对照数据的概率，其中测试数据对应于阳性对照数据而不是阴性对照数据的概率表示测试对象具有结肠直肠癌相对于没有结肠直肠癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式